We just published in The Lancet Oncology a very important paper regarding the new FDA guidance on overall survival assessment in cancer drug trials. Right in time for #ESMO25. Please do read. I promise you that you’ll learn something that’s applicable broadly. And follow along this

CAR-T in PCNSL #lymsm - 67 pts, 25% CSF+, 12% eye+ - 57% axicel, 30% tisacel - 58% CR, 1-yr PFS 50%, 1-yr OS 66% - 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28% - 27% G3+ ICANS! Almost all got bridging; would love to know which agents. academic.oup.com/neuro-oncology…

Eddie Cliff The LOC have previously published their experience: pubmed.ncbi.nlm.nih.gov/38586986/ but nice to see this expanded dataset. It would be wonderful if we could access this therapy for PCNSL in other jurisdictions.

🚗💥 CAAR-T therapy — not science fiction anymore. Imagine T cells trained to hunt only the rogue B cells causing autoimmunity — leaving the rest untouched. From pemphigus to lupus nephritis and type 1 diabetes, trials are just beginning. Precision autoimmunity is here. 🔥

Updated mSMART guidelines on treatment of newly diagnosed myeloma. Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. msmart.org/mm-treatment-g…

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Check out our most recent publication in Blood Cancer Journal evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. nature.com/articles/s4140… Nicholas Short MD Hagop Kantarjian,MD #Leusm #ALLsm

Very nice editorial on our recent Blood paper! ashpublications.org/blood/article/…

We just published our paper comparing eligibility criteria for #CAR-T vs autoSCT. They are NOT the same! Key message: Most patients are eligible for CAR-T, even with significant comorbidities. Collaboration with other specialists is key to optimizing patients clinical situation.

Every patient with relapsed lymphoma deserves an official consultation with a CAR-T expert. CAR-T cell therapy has been associated with improved overall survival in DLBCL, and longer follow-up now suggests the potential for cure in both aggressive and indolent lymphomas. 1/3

CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

For patients with relapsed or refractory multiple #myeloma, CAR-T therapy offers a powerful treatment option by reprogramming the patient’s own T-cells to target myeloma cells. But when is CAR-T the right time for you? #mmsm youtu.be/2AVTnGa4jzk?si…

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study Blood Cancer Journal nature.com/articles/s4140…

Designing a strong bridge to CAR-T cells with bispecifics ow.ly/TSpT50Xh8x8 #immunobiologyandimmunotherapy

Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma aacrjournals.org/clincancerres/…

Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Why new vaccines? A friend who was a brilliant science topper, working for a tech giant in the US was visiting his home town in South Canara. He was married to an ayurvedic doctor. They both were swept away by the #Antivaxx movement and had declined most vaccines. Their tween

A pharmacokinetic/pharmacodynamic model predicts tumor debulking improves CAR T-cell efficacy in Large B-Cell Lymphoma aacrjournals.org/bloodcancerdis…

🚨 Big news in cellular therapy! 🚨 FACT and JACIE have officially released the Standards for Hematopoietic Cellular Therapy (HCT), 9th Edition and the Standards for Immune Effector Cells (IEC), 3rd Edition demonstrating our ongoing commitment to promoting quality, patient

📢 Now available: Foundation for Accreditation of Cellular Therapy and #JACIE 9th Edition HCT Standards + 3rd Edition IEC Standards! 👏 A key milestone and example of the ongoing commitment to promoting high quality and patient safety in #HCT and #CellularTherapy worldwide. ⤵️  📌 ebmt.org/ebmt/news/fact…